Clinical Trial Update: Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial of adjuvant ribociclib with endocrine therapy for HR+/HER2- intermediate-risk early breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 3 | Status: WITHDRAWN